CU24139B1 - CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE - Google Patents

CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE

Info

Publication number
CU24139B1
CU24139B1 CU20130012A CU20130012A CU24139B1 CU 24139 B1 CU24139 B1 CU 24139B1 CU 20130012 A CU20130012 A CU 20130012A CU 20130012 A CU20130012 A CU 20130012A CU 24139 B1 CU24139 B1 CU 24139B1
Authority
CU
Cuba
Prior art keywords
granulocit
colonia
csf
conjugate
stimulating factor
Prior art date
Application number
CU20130012A
Other languages
Spanish (es)
Other versions
CU20130012A7 (en
Inventor
Tatyana Veniaminovna Chernovskaya
Dmitriy Valentinovich Morozov
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Angelina Vsevolodovna Klenova
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24139(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of CU20130012A7 publication Critical patent/CU20130012A7/en
Publication of CU24139B1 publication Critical patent/CU24139B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CU20130012A 2010-08-13 2011-07-19 CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE CU24139B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent
PCT/RU2011/000532 WO2012021088A1 (en) 2010-08-13 2011-07-19 A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol

Publications (2)

Publication Number Publication Date
CU20130012A7 CU20130012A7 (en) 2013-04-19
CU24139B1 true CU24139B1 (en) 2015-12-23

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20130012A CU24139B1 (en) 2010-08-13 2011-07-19 CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE

Country Status (18)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
PH (1) PH12012502426A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
KR20160113302A (en) 2014-02-18 2016-09-28 칠드런'스 하스피틀 로스 앤젤레스 Compositions and methods for treating neutropenia
JP6742300B2 (en) 2014-07-14 2020-08-19 ジェンノヴァ バイオファーマシューティカルズ リミテッド Novel process for purification of rHu-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
CN115297844A (en) * 2020-03-17 2022-11-04 德拉格雷丘尔公司 Liquid formulation of GM-CSF for inhalation
JP2023518412A (en) * 2020-03-20 2023-05-01 アムジェン インコーポレイテッド Determination of the free N-terminus of pegfilgrastim using acid protease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
MX2008009125A (en) * 2006-01-18 2008-10-23 Qps Llc Pharmaceutical compositions with enhanced stability.
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc MODIFIED RIBONUCLEASES

Also Published As

Publication number Publication date
DOP2013000003A (en) 2013-07-31
PH12012502426A1 (en) 2021-06-02
CR20130020A (en) 2013-02-20
EA019043B1 (en) 2013-12-30
SG187572A1 (en) 2013-03-28
RU2446173C1 (en) 2012-03-27
RS20130094A1 (en) 2013-08-30
MY160732A (en) 2017-03-15
CL2013000400A1 (en) 2013-07-26
KR101549457B1 (en) 2015-09-02
PE20131085A1 (en) 2013-10-10
EA201101035A1 (en) 2012-02-28
ECSP13012399A (en) 2013-05-31
MA34525B1 (en) 2013-09-02
NI201300007A (en) 2014-05-26
CO6670557A2 (en) 2013-05-15
CN103140499B (en) 2014-12-17
WO2012021088A1 (en) 2012-02-16
CU20130012A7 (en) 2013-04-19
CN103140499A (en) 2013-06-05
KR20130043167A (en) 2013-04-29

Similar Documents

Publication Publication Date Title
CU24139B1 (en) CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE
SMT201700008B (en) PHARMACEUTICAL COMPOSITION
SMT201600350B (en) PHARMACEUTICAL COMPOSITIONS
BR112012022746A2 (en) use of amisulpride as antiemetic
LT3222272T (en) PHARMACEUTICAL COMPOSITION OF CARBETOCINE
EP2595532A4 (en) IMPLANTABLE DIELECTROMETER
PT2637514E (en) GEL COMPOSITION
SMT201700050B (en) THERMOGELIFYING ANESTHETIC COMPOSITIONS
DK3257890T3 (en) CROSS-BINDING COMPOSITION
DK2912074T4 (en) DERMAL INJECTIVE STERILE COMPOSITION
BR112013010000A2 (en) catheter apparatus
BR112012031203A2 (en) arrangement of two rail segments
DK2525798T3 (en) ANESTHETIC FORMULATION
EP2641343A4 (en) CONFIGURATION OF SUBFRAME
EP2586811A4 (en) HIERÉRO-POLYETHYLENE GLYCOL BRANCHED AND INTERMEDIATE
BR112012030765A2 (en) sterile liquid composition
EP2550961A4 (en) SOLID PREPARATION
FR2987086B1 (en) LINEAR JOINT OF PLATFORM INTER-AUBES
DK2444068T3 (en) Brimonide gel preparation
CO6801722A2 (en) Pharmaceutical compositions
EP2550960A4 (en) SOLID PREPARATION
EP2609931A4 (en) IMMUNOGENIC COMPOSITION
ME02992B (en) AGOMELATIN INTERMEDIATES AND THEIR PREPARATION PROCEDURES
EP2886608A4 (en) COMPOSITION OF POLYETHER POLYAMIDE
EP2851085A4 (en) STERILIZED COMPOSITION